RSA Viewpoints
Hiring international executives and the (true) costs of failure
A tale of two …points of view? “It was the best of times, it was the worst of times, it was the age of...
Building talent and saving lives
London was the setting last week for the 25th Annual Meeting of the International Society for Cellular Therapy. The huge increase of clinical trials...
RSA Talent Equity® | Biotech IPOs and Deals 2016
In our latest Talent Equity® Report, we examine the performance of biotech leaders whose companies IPO’d or were active in deal-making in 2016. Leaders...
A Report from BIO-Europe Spring 2017
The blue skies and balmy weather of Barcelona were the perfect backdrop for BIO-Europe Spring this year. The 2,400 biotech pros at the conference...
Behavioural profiling in the search for medical affairs professionals
In pharmaceutical companies, medical affairs professionals play a vital yet complex role: acting as a bridge between the medical and commercial groups, and as...
Report from J.P. Morgan 2017
So, that’s the J.P. Morgan Healthcare Conference done for another year. For just a few highly energised days it felt as if nearly every...
A report from the 2018 J.P.Morgan Healthcare Conference
A quiet JPM18? I don’t think so. One thing I learned at JPM18 was that journalists see the world differently to me. There were...
Shaping up for growth in a world of change
The 34th FT Global Pharmaceutical and Biotechnology Conference brought together life science and pharma companies as well as emerging new players. Discussions centered on industry challenges,...
Change for the better
Talent is more global now than ever. In light of the recent Brexit vote and the fact that demand for talent in Europe is...
A year of breakthroughs at ESMO as the big data revolution transforms cancer research talent
ESMO, Europe’s most important cancer congress concluded this week with a record breaking attendance of over 20,000 people. The buzz, not for the first...
Building a floating city on the Great Lake of data: Pharma’s 2016 challenge
The life sciences industry is a knowledge business. The data from scientific research, drug development, billions of interactions with customers and compliance with regulations...
Interim leaders are not ‘temps’ – choose wisely and reap the rewards
We’re all familiar with the concept – there’s an absence at work and we need some cover. A quick Google search and we send...
LEAP HR Life Sciences: HR with Impact and Agile Biotechs
Last week RSA attended LEAP HR: Life Sciences in Boston, Massachusetts. From past experience we were expecting a high value event and we were not disappointed....
Labelling of an Interim (or consultant; or freelancer)
I am often asked what defines an Executive Interim and the online community often seeks to debate this subject too. Veterans in the field...
What next for EU and UK biotech boards?
In light of the UK’s decision to leave the EU, it’s worth revisiting our recent Talent Equity® report on what makes successful biotech boards. The question...
Change in regulatory environment and the impact on talent
A view from the TOPRA Summit I approached the first TOPRA Summit in London at the end of May knowing that the world of healthcare...
Ipsen choose RSA Group as strategic partner for executive talent acquisition in Europe
We have been selected by Ipsen, one of the world’s leading innovators in patient care, as their chosen strategic partner in Europe for executive...